September 04, 2025
First-Half 2025 Financial Results
Consolidated sales amounted to €2,044 million in the first-half of 2025 from €1,902 million in the prior year period, a +9.4% like-for-like growth.
Media & Press relations
Our latest press releases
Swipe for more
-
August 18, 2025
bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini
bioMérieux today announces that its BIOFIRE® SPOTFIRE® R/ST Panel Mini has received U.S. FDA 510(k) clearance and CLIA waiver for the addition of Anterior Nasal Swab as a validated specimen type for this panel. -
June 16, 2025
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. -
June 03, 2025
VETFIRE™: bioMérieux launches cutting-edge equine infectious respiratory disease testing
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of VETFIRE™, a ready-to-use PCR kit that makes testing for equine infectious respiratory diseases easier and faster.
Media contacts
Olivier Rescanière
Phone: (+33) (0)4 78 87 20 00
Email: media@biomerieux.com
_____
Romain Duchez
Phone: (+33) (0)4 78 87 20 00
Email: media@biomerieux.com
Corporate Library
